Smith & Nephew (SNN) Financial Analysis & Valuation | Quarter Chart
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include ... more
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells m... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $12.90B | Exchange | NYSE |
| Sector | Healthcare | Industry | Medical - Devices |
| Country | GB | CEO | Deepak S. Nath |
| IPO Date | 1999-11-16 | CAGR | 5.96% |
| Employees | 18,362 | Website | www.smith-nephew.com |
| Div. Yield | 62.71% | Payout Ratio | 52% |
| Buy Back Yield | 117.29% | Total Yield | 180% |
SNN chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $17.25B | P/E | 20.81 | Forward P/E | 12.8 | PEG | 3.68 |
| P/S | 0.09 | P/B | 0.11 | P/CF | 0.4 | P/FCF | 0.62 |
| Sales | $12.24B | Sales 1Y | 11.4% | Sales 3Y | 27.05% | Sales 5Y | 30.83% |
| EPS | $1.48 | EPS 1Y | 114.88% | EPS 3Y | 3.59% | EPS 5Y | 39.78% |
| Sales QoQ | -3.31% | EPS QoQ | -7.89% | Sales QoQ Avg | 2.41% | EPS QoQ Avg | 10.92% |
| Gross Margin | 68.18% | Operating Margin | 16.69% | Profit Margin | 10.08% | ROCE | 11.81% |
| ROA | 6% | ROE | 12% | Altman Z Score | 4.2 | Piotroski Score | 7 |
| Current Ratio | 2.14 | Quick Ratio | 1.11 | Cash Ratio | 0.37 | Op. CF Ratio | 0.22 |
| Debt/Equity | 0.73 | Debt/Assets | 0.34 | Lt Debt/Equity | 0.62 | Lt Debt/Cap. | 0.37 |
| Intrst Cov. | 6.66 | Inventory Turnover | 0.96 | Asset Turnover | 0.58 | Receivables Turnover | 4.17 |
| Enterprise Value | $17.25B | P/E Ratio | 20.81 |
| Forward P/E | 12.8 | PEG Ratio | 3.68 |
| P/S Ratio | 0.09 | P/B Ratio | 0.11 |
| P/CF Ratio | 0.4 | P/FCF Ratio | 0.62 |
| EPS | $1.48 | EPS Growth 1Y | 114.88% |
| EPS Growth 3Y | 3.59% | EPS Growth 5Y | 39.78% |
| Revenue Growth 1Y | 11.4% | Gross Margin | 68.18% |
| Operating Margin | 16.69% | Profit Margin | 10.08% |
| ROE | 12% | ROA | 6% |
| ROCE | 11.81% | Current Ratio | 2.14 |
| Quick Ratio | 1.11 | Cash Ratio | 0.37 |
| Debt/Equity | 0.73 | Interest Coverage | 6.66 |
| Altman Z Score | 4.2 | Piotroski Score | 7 |
Smith & Nephew (SNN) valuation & financials
Smith & Nephew (SNN) has a market capitalization of $12.90B and trades at a price-to-earnings ratio of 20.8. It operates in the Healthcare sector (Medical - Devices).
Smith & Nephew's revenue grew +11.4% over the last year.
Smith & Nephew's next earnings report is scheduled for February 23, 2027 (provider scheduled date); analysts estimate EPS of $0.94. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)